Monkeypox Vaccine use while Breastfeeding
Medically reviewed by Drugs.com. Last updated on Feb 1, 2025.
Monkeypox Vaccine Levels and Effects while Breastfeeding
Summary of Use during Lactation
Worldwide, three vaccines are available for monkeypox (Mpox), known as MVA-BN, ACAM-2000 and LC16. Only MVA-BN (Jynneos) and ACAM-2000 are available in the United States. The MVA-BN vaccine does not replicate and behaves like a non-live vaccine. The ACAM-2000 vaccine is live and is contraindicated in breastfeeding. No information is available on the LC16 (minimally replicating) vaccine during breastfeeding. The US Centers for Disease Control and Prevention and the World Health Organization state that if the MVA-BN vaccine can be offered to breastfeeding women who are otherwise eligible and breastfeeding need not be discontinued after vaccination. The risks and benefits of the vaccine should be discussed with the patient using shared decision-making.[1-3]
Individuals with Mpox disease should feed their infants with pasteurized donor milk or infant formula until all of their lesions are healed. Numerous other safety precautions are advised for mothers with Mpox.
Drug Levels
Maternal Levels. Milk samples were collected from a nursing mother the day before and at 2, 6, 20, 36, and 72 hours and 7 and 14 days and 10 weeks after receiving the first dose of intradermal smallpox and monkeypox vaccine, live, nonreplicating (Jynneos, Bavarian Nordic). A second dose was given at 12 weeks and milk samples were taken at 3 hours, 3 days, and 2 and 12 weeks after the dose. Milk IgA against 3 vaccine antigens increased 0.9- to 2.2-fold 2 weeks after dose 2, reaching a peak titer increase of 1.1- to 2.7-fold at 12 weeks after dose 2. Secretory antibody levels increased to 1.1- to 2-fold at 2 weeks after dose 2 and reached a peak of 2- to 3.2-fold increase at the 12-week time point. IgA and secretory antibody responses in milk exhibited correlation, suggesting most milk IgA was secretory IgA. No vaccine protein or DNA components were detected in the milk samples.[4]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
-
Centers for Disease Control and Prevention. Mpox clinical care and treatment during pregnancy. January 30, 2025. https://www
.cdc.gov/mpox /hcp/clinical-care/pregnancy.html - 2.
-
World Health Organization. Smallpox and mpox (orthopoxviruses): WHO position paper, August 2024. WHO Weekly Epidemiological Record 2024;99:429–56. https://www
.who.int/publications /i/item/who-wer-9934-429-456 - 3.
-
Hombach J., Lewis R., Holten J. V., et al. Breastfeeding mothers in DR Congo should have access to the mpox vaccine. Lancet Glob Health 2024;12:e1932. [PubMed: 39577965]
- 4.
-
Yang X, Fox A, DeCarlo C, et al. Unique kinetics of the human milk antibody response to JYNNEOS vaccine for prevention of monkey pox: A case study. Breastfeed Med 2024;19:974–9. [PMC free article: PMC11655390] [PubMed: 39360771]
Substance Identification
Substance Name
Monkeypox Vaccine
Drug Class
Breast Feeding
Lactation
Milk, Human
Vaccines
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.